Skip to main content
Log in

Metoclopramide, domperidone and dopamine in man: actions and interactions

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The effects of oral doses of the dopamine antagonist antiemetics metoclopramide and domperidone on baseline and dopamine stimulated renal function and systemic haemodynamics were assessed in a placebo controlled crossover study in 9 healthy volunteers.

Metoclopramide did not change baseline ERPF, GFR or FF over 2 h post dosing but it significantly reduced baseline UNaV, UKV, urine flow, urinary dopamine excretion, supine and erect diastolic blood pressure and supine systolic blood pressure. Domperidone and placebo did not cause these effects.

Metoclopramide caused a marked rise and domperidone a small fall in plasma aldosterone concentration (PAC) but placebo was without effect. Neither antiemetic altered plasma renin activity (PRA) but a small fall occurred with placebo.

Two hours after pretreatment with placebo dopamine (2 μg/kg/min) increased effective renal plasma flow (ERPF), glomerular filtration rate (GFR), sodium excretion rate (UNaV), urine flow rate, urinary dopamine excretion rate, supine systolic blood pressure and supine and erect pulse rate and decreased the potassium excretion rate (UKV), filtration fraction (FF) and supine diastolic blood pressure.

Metoclopramide pretreatment, did not attenuate the dopamine induced rise in ERPF, GFR, urine flow, urinary dopamine excretion or supine systolic blood pressure but it did attenuate the rise in pulse rate, the fall in diastolic pressure, and the antikaliuretic effect of dopamine leading to a net kaliuresis when compared to placebo. Domperidone was similar to placebo.

Neither metoclopramide nor domperidone given orally caused clinically important antagonism of the renal haemodynamic effects of dopamine. However the effects of metoclopramide on blood pressure and electrolyte excretion may have clinical importance.

Metoclopramide has significant pharmacodynamic effects which are probably not due to DA2 antagonism but may be mediated by DA1 antagonism or be non-specific.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

DA:

dopamine

ERPF:

effective renal plasma flow

FF:

filtration fraction

GFR:

glomerular filtration rate

PAC:

plasma aldosterone concentration

PRA:

plasma renin activity

UV:

urine flow rate

UNaV:

urinary sodium excretion rate (natriuresis)

UKV:

urinary potassium excretion rate (kaliuresis)

HPLC:

high performance liquid chromatography.

References

  1. McDonald RH, Goldberg LI, McNay JL, Tuttle EP (1964) Effects of dopamine in man: augmentation of sodium excretion, glomerular filtration rate and renal plasma flow. J Clin Invest 43: 1116–1124

    Google Scholar 

  2. Smit AJ, Meijer S, Wessling H, Reitsma WD, Donker AJM (1987) The dose-response effect of intravenous dopamine on renal function in normal man and in patients with renal disease. Kidney Int 31: 1044–1045

    Google Scholar 

  3. Felder RA, Felder CC, Eisner GM, Jose P (1989) Renal dopamine receptors. In: Peripheral actions of dopamine. Bell C, McGrath B (eds), MacMillan, New York, pp 124–140

    Google Scholar 

  4. Smit AJ, Meijer S, Wesseling H, Donker AMJ, Reitsma WD (1988) Effect of metoclopramide on dopamine-induced changes in renal function in healthy controls and in patients with renal disease. Clin Sci 75: 421–428

    Google Scholar 

  5. Cavero I, Massingham R, Lefevre-Borg T (1982) Peripheral dopamine receptors, potential sites for a new class of antihypertensive agents. Part 1: subclassification and functional description. Life Sci 31: 939–948

    Google Scholar 

  6. Kohli JD, Glock D, Goldberg LI (1982) Differential antagonism of postsynaptic (DA1) and presynaptic (DA2) peripheral dopamine receptors by substituted benzamides. In: Rotrosen J, Stanley M (eds) The benzamides: pharmacology, neurobiology and clinical aspects. Raven Press, New York, pp 97–108

    Google Scholar 

  7. Langer SZ (1981) Presynaptic regulation of the release of catecholamines. Pharmacol Rev 32: 337–367

    Google Scholar 

  8. Jose PA, Felder RA, Robillard JE, Felder CC, Eisner GM (1986) Dopamine-2 receptors in the canine kidney. Kidney Int 29: 385

    Google Scholar 

  9. Felder RA, Belcher M, Eisner GM, Jose PA (1984) Cortical tubular and glomerular dopamine receptors in the rat kidney. Am J Physiol 246: F557-F568

    Google Scholar 

  10. Kohli JD, Glock D, Goldberg LI (1983) Selective DA2 versus DA1 antagonist activity of domperidone in the periphery. Eur J Pharmacol 89: 137–141

    Google Scholar 

  11. Dawborn JK (1965) Application of Heyrousky's inulin method to automatic analysis. Clin Chim Acta 12: 63–66

    Google Scholar 

  12. Harvey RB, Brothers AJ (1962) Renal extraction of para-aminohippurate and creatinine measured by continuous in vivo sampling of arterial and renal vein blood. Ann New York Acad Sci 120: 46–54

    Google Scholar 

  13. Haber E, Koerner T, Page LB, Kliman B, Purnode A (1969) Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol 29: 1349–1355

    Google Scholar 

  14. Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H (1981) On the pharmacokinetics of domperidone in animals and man IV: The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokin 6: 61–70

    Google Scholar 

  15. Bateman DN, Gokal R, Dodd TRP, Blain PG (1981) The pharmacokinetics of single doses of metoclopramide in renal failure. Eur J Clin Pharmacol 19: 437–441

    Google Scholar 

  16. Anton AH, Sayre DF (1964) The distribution of dopamine and dopa in various animals and a method of their determination in diverse biological material. J Pharmacol Exper Ther 145: 326–336

    Google Scholar 

  17. MacDonald TM, Jeffrey RF, Freestone S, Lee MR (1988) (+)-sulpiride attenuates the renal effects of gamma-L-glutamyl-L-dopa in man. Br J Clin Pharmacol 25: 203–212

    Google Scholar 

  18. Stote RM, Dubb JW, Familiar RG, Erb BB, Alexander F (1983) A new oral vasodilator, fenoldopam. Clin Pharmacol Ther 34: 309–315

    Google Scholar 

  19. Hahn RA, Wardell JR (1980) Antagonism of the renal vasodilation activity of dopamine by metoclopramide. Naunyn Schmiedebergs Arch Pharmacol 314: 177–182

    Google Scholar 

  20. Albibi R, McCallu RW (1983) Metoclopramide: Pharmacology and clinical applications. Ann Int Med 98: 86–95

    Google Scholar 

  21. Braley LM, Menachery AI, Williams GH (1983) Specificity of metoclopramide in assessing the role of dopamine in regulating aldosterone secretion. Endocrinology 112: 1352–1357

    Google Scholar 

  22. Fang VS, Shian LR (1981) A seratonergic mechanism of the prolactin-stimulating action of metoclopramide. Endocrinology 108: 1622–1627

    Google Scholar 

  23. Spedding M (1980) Effects of metoclopramide and isoprenaline in the rat vas deferens: interactions with α-adrenoceptors. Br J Pharmacol 71: 113–120

    Google Scholar 

  24. Bevilacqua M, Norbiato G, Raggi U, Micossi P, Baggio E, Prandeli M (1980) Dopaminergic control of serum potassium. Metabolism 29: 306–310

    Google Scholar 

  25. Sheridan C, Chardra P, Jacinto M, Greenwald ES (1982) Transient hypertension after high doses of metoclopramide. N Engl J Med 307: 1346

    Google Scholar 

  26. Kuchel O, Buu NT, Hamet P, Larochelle P (1985) Effect of metoclopramide on plasma catecholamine release in essential hypertension. Clin Pharmacol Ther 37: 372–375

    Google Scholar 

  27. Mannelli M, Feo ML, Maggi M, Salvetti A, Giusti G, Serio M (1985) Does endogenous dopamine modulate human sympathetic activity through DA2 receptors? Eur J Clin Pharmacol 29: 159–164

    Google Scholar 

  28. Ennis C, Cox B (1980) The dopamine receptor antagonist domperidone is also a competitive antagonist at alpha1-adrenoceptors. J Pharm Pharmacol 32: 434

    Google Scholar 

  29. Osborne RJ, Slevin ML, Hunter RW, Hamer J (1985) Cardiotoxicity of intravenous domperidone. Lancet II: 385

    Google Scholar 

  30. Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H (1981) On the pharmacokinetics of domperidone in animals and man IV: The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokin 6: 61–70

    Google Scholar 

  31. Ross-Lee LM, Eadie MJ, Hooper MJ, Bochner F (1981) Single-dose pharmacokinetics of metoclopramide. Eur J Clin Pharmacol 20: 465–471

    Google Scholar 

  32. Graffner C, Lagerstrom P, Lundborg P, Ronn O (1979) Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography. Br J Clin Pharmacol 8: 469–474

    Google Scholar 

  33. Bateman DN, Kahn C, Davies DS (1980) The pharmacokinetics of metoclopramide in man with observations in the dog. Br J Clin Pharmacol 9: 371–377

    Google Scholar 

  34. Carey RM, Thorner MO, Ortt EM (1980) Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. J Clin Invest 66: 10–18

    Google Scholar 

  35. Norbiato GM, Bevilacqua M, Raggi D, Micossi P, Moroni C (1977) Metoclopramide increases aldosterone secretion in man. J Clin Endocrinol Metab 45: 1313–1316

    Google Scholar 

  36. Dupont AG, Vanderniepen P, Smitz JJ, Six RO (1985) Stimulation of aldosterone secretion by metoclopramide is not affected by chronic converting enzyme inhibition. Eur J Clin Pharmacol 29: 207–210

    Google Scholar 

  37. Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC (1983) Metoclopramide: an updated review of its pharmacological properties and clinical use. Drugs 25: 451–494

    Google Scholar 

  38. North RH, McCallum RW, Contino C, Havelick J (1980) Tonic dopaminergic suppression of plasma aldosterone. J Clin Endocrinol Metab 51: 64–69

    Google Scholar 

  39. Sowers JR, Brickman AS, Sowers DK, Berg G (1981) Dopaminergic modulation of aldosterone secretion in man is unaffected by glucocorticoids and angiotensin blockade. J Clin Endocrinol Metab 52: 1078–1084

    Google Scholar 

  40. Ganguly A (1984) Dopaminergic regulation of aldosterone secretion: how credible? Clin Sci 66: 631–637

    Google Scholar 

  41. Fraser R (1987) Dopamine regulation of aldosterone secretion: an open question? J Endocrinol 112: 179–181

    Google Scholar 

  42. Breckenridge A, Orme M, Dollery CT (1971) The effects of dopamine on renal blood flow in man. Eur J Clin Pharmacol 3: 131–136

    Google Scholar 

  43. Hollenberg NK, Adams DF, Mendell P, Abrams HL, Merril JP (1973) Renal vascular responses to dopamine: haemodynamic and angiographic observations in normal man. Clin Sci Mol Med 45: 733–742

    Google Scholar 

  44. Levinson PD, Goldstein DS, Munson PJ, Gill JR, Keiser HR (1985) Endocrine, renal and haemodynamic responses to graded dopamine infusions in normal men. J Clin Endocrinol Metab 60: 821–826

    Google Scholar 

  45. Orme ML, Breckenridge A, Dollery CT (1973) The effects of long term administration of dopamine on renal function in hypertensive patients. Eur J Clin Pharmacol 6: 150–155

    Google Scholar 

  46. Hughes A, Thom S, Martin G, Redman D, Hasan S, Sever P (1986) The action of a dopamine (DA1) receptor agonist, fenoldopam in human vasculature in vivo and in vitro. Br J Clin Pharmacol 22: 535–540

    Google Scholar 

  47. Jeffrey RF, MacDonald TM, Critchley JAJH, Lee MR (1986) Urinary dopamine-sodium relationships under basal and frusemide-stimulated states. Scot Med J 31: 213 (Abstract)

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

MacDonald, T.M. Metoclopramide, domperidone and dopamine in man: actions and interactions. Eur J Clin Pharmacol 40, 225–230 (1991). https://doi.org/10.1007/BF00315200

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00315200

Key words

Navigation